Post Lung Transplant: The following questions pertain to the post-transplant period.
Does your center employ post-transplant, pharmacologic anti-fungal prophylaxis?
○ Yes
○ No
○ Unsure
What prompts pharmacologic anti-fungal prophylaxis post-transplantation (Select all that apply)?
□ Our center uses universal post-transplant anti-fungal prophylaxis
□ Diagnosis of Cystic Fibrosis
□ Patient’s occupation
□ Patient’s geographic location
□ Pre-transplant airway colonization with Aspergillus sp.
□ Post-transplant airway colonization with Aspergillus sp.
□ Pre-transplant airway colonization with other molds
□ Post-transplant airway colonization with other molds
□ Pre-transplant airway colonization with non-Candida yeast
□ Pre-transplant airway colonization with Candida sp.
□ Post-transplant airway colonization with non-Candida yeast
□ Post-transplant airway colonization with Candida sp.
□ Presence of bronchiectasis without a diagnosis of Cystic Fibrosis
□ Other
Please describe “Other”
What is the goal of post-transplant anti-fungal prophylaxis (Select all that apply)?
□ Prevention of post-transplantation tracheobronchitis
□ Prevention of post-transplantation invasive fungal infection
□ Prevention of Bronchiolitis Obliterans Syndrome/ Chronic Lung Allograft Dysfunction
□ Other
Please describe “Other”
What anti-fungal agent(s) is preferred by your center for post-transplant anti-fungal prophylaxis? (You may select up to 1 topical,1 in-hospital systemic agent, and 1 post-hospital systemic agent)
Topical agents
○ Aerosolized amphotericin B
○ Other
○ No topical agent is used
Please describe “Other”
In-hospital systemic agents
○ Amphotericin
○ Anidulafungin
○ Caspofungin
○ Fluconazole
○ Micafungin
○ Isavuconazole
○ Itraconazole
○ Posaconazole
○ Voriconazole
○ Other
○ No in-hospital systemic agent is used
Please describe “Other”
Post-hospital systemic agents
○ Amphotericin
○ Anidulafungin
○ Caspofungin
○ Fluconazole
○ Micafungin
○ Isavuconazole
○ Itraconazole
○ Posaconazole
○ Voriconazole
○ Other
○ No post-hospital systemic agent is used
Please describe “Other”
What is the average duration of post-transplant topical (i.e. nebulized or aerosolized) anti-fungal prophylaxis?
○ In-hospital post-transplant surgery only
○ Less than 3 months
○ 3 to 6 months
○ Greater than 6 months but less than 12 months
○ 12 months but less than lifelong
○ Lifelong
What is the average duration of post-transplant systemic antifungal prophylaxis?
○ In-hospital post-transplant surgery only
○ Less than 3 months
○ 3 to 6 months
○ Greater than 6 months but less than 12 months
○ 12 months but less than lifelong
○ Lifelong
What is the dosing method used for your center’s preferred post-transplant triazole therapy? Triazole therapy includes: fluconazole, voriconazole, itraconazole, posaconazole, isavuconazole.
○ Standard uniform dosing regardless of serum anti-fungal levels
○ Dosed to a serum “detectable” anti-fungal level
○ Dosed to a specific targeted serum anti-fungal level
○ Other
Please describe “Other”
Do patients less than 3 months post-lung transplant receive inhaled amphotericin for prophylaxis?
○ All patients receive inhaled amphotericin during this post-transplant period
○ No patients receive inhaled amphotericin during this post-transplant period
○ Some patients receive inhaled amphotericin during this post-transplant period
Which patients receive inhaled amphotericin less than 3 months post-lung transplant (Select all that apply)?
□ Patients with a diagnosis of Cystic Fibrosis
□ Patients with bronchiectasis without a diagnosis of Cystic Fibrosis
□ Patients with pre-transplant Aspergillus sp. airway colonization regardless of underlying pulmonary co-morbidities
□ Patients with post-transplant Aspergillus sp. airway colonization regardless of underlying pulmonary co-morbidities
□ Patients with pre-transplant mold airway colonization (other than Aspergillus sp.) regardless of underlying pulmonary co-morbidities
□ Patients with post-transplant mold airway colonization (other than Aspergillus sp.) regardless of underlying pulmonary co-morbidities
□ Patients with pre-transplant non-Candida yeast airway colonization regardless of underlying pulmonary co-morbidities
□ Patients with post-transplant non-Candida yeast airway colonization regardless of underlying pulmonary co-morbidities
□ Patients with pre-transplant Candida sp. airway colonization regardless of underlying pulmonary co-morbidities
□ Patients with post-transplant Candida sp. airway colonization regardless of underlying pulmonary co-morbidities
□ Patients with pre-transplant invasive Aspergillus sp. Infection
□ Patients with pre-transplant invasive mold (other than Aspergillus sp.) infection
□ Patients with pre-transplant non-Candida yeast infection
□ Patients with pre-transplant Candida sp. infection
□ Other
Please describe “Other”
Do patients less than 3 months post-lung transplant receive systemic triazole(s) for prophylaxis? Triazole therapy includes: fluconazole, voriconazole, itraconazole, posaconazole, isavuconazole.
○ All patients receive systemic triazole therapy during this post-transplant period
○ No patients receive systemic triazole therapy during this post-transplant period
○ Some patients receive triazole(s) during this post-transplant period
Which patients receive triazole(s) less than 3 months post-lung transplant (Select all that apply)?
□ Patients with a diagnosis of Cystic Fibrosis
□ Patients with bronchiectasis without a diagnosis of Cystic Fibrosis
□ Patients with pre-transplant Aspergillus sp. airway colonization regardless of underlying pulmonary co-morbidities
□ Patients with post-transplant Aspergillus sp. airway colonization regardless of underlying pulmonary co-morbidities
□ Patients with pre-transplant mold airway colonization (other than Aspergillus sp.) regardless of underlying pulmonary co-morbidities
□ Patients with post-transplant mold airway colonization (other than Aspergillus sp.) regardless of underlying pulmonary co-morbidities
□ Patients with pre-transplant non-Candida yeast airway colonization regardless of underlying pulmonary co-morbidities
□ Patients with post-transplant non-Candida yeast airway colonization regardless of underlying pulmonary co-morbidities
□ Patients with pre-transplant Candida sp. airway colonization regardless of underlying pulmonary co-morbidities
□ Patients with post-transplant Candida sp. airway colonization regardless of underlying pulmonary co-morbidities
□ Patients with pre-transplant invasive Aspergillus sp. Infection
□ Patients with pre-transplant invasive mold (other than Aspergillus sp.) infection
□ Patients with pre-transplant non-Candida yeast infection
□ Patients with pre-transplant Candida sp. infection
□ Other
Please describe “Other”
Do patients less than 3 months post-lung transplant receive systemic echinocandin(s) for prophylaxis? Echinocandin therapy includes: caspofungin, micafungin, anidulafungin.
○ All patients receive systemic echinocandin during this post-transplant period
○ No patients receive systemic echinocandin therapy during this post-transplant period
○ Some patients receive echinocandin(s) during this post-transplant period
Which patients receive systemic echinocandin(s) less than 3 months post-lung transplant (Select all that apply)?
□ Patients with a diagnosis of Cystic Fibrosis
□ Patients with bronchiectasis without a diagnosis of Cystic Fibrosis
□ Patients with pre-transplant Aspergillus sp. airway colonization regardless of underlying pulmonary co-morbidities
□ Patients with post-transplant Aspergillus sp. airway colonization regardless of underlying pulmonary co-morbidities
□ Patients with pre-transplant mold airway colonization (other than Aspergillus sp.) regardless of underlying pulmonary co-morbidities
□ Patients with post-transplant mold airway colonization (other than Aspergillus sp.) regardless of underlying pulmonary co-morbidities
□ Patients with pre-transplant non-Candida yeast airway colonization regardless of underlying pulmonary co-morbidities
□ Patients with post-transplant non-Candida yeast airway colonization regardless of underlying pulmonary co-morbidities
□ Patients with pre-transplant Candida sp. airway colonization regardless of underlying pulmonary co-morbidities
□ Patients with post-transplant Candida sp. airway colonization regardless of underlying pulmonary co-morbidities
□ Patients with pre-transplant invasive Aspergillus sp. Infection
□ Patients with pre-transplant invasive mold (other than Aspergillus sp.) infection
□ Patients with pre-transplant non-Candida yeast infection
□ Patients with pre-transplant Candida sp. infection
□ Other
Please describe “Other”
Do patients less than 3 months post-lung transplant receive systemic amphotericin for prophylaxis?
○ All patients receive systemic amphotericin during this post-transplant period
○ No patients receive systemic amphotericin during this post-transplant period
○ Some patients receive systemic amphotericin during this post-transplant period
Which patients receive systemic amphotericin less than 3 months post-lung transplant (Select all that apply)?
□ Patients with a diagnosis of Cystic Fibrosis
□ Patients with bronchiectasis without a diagnosis of Cystic Fibrosis
□ Patients with pre-transplant Aspergillus sp. airway colonization regardless of underlying pulmonary co-morbidities
□ Patients with post-transplant Aspergillus sp. airway colonization regardless of underlying pulmonary co-morbidities
□ Patients with pre-transplant mold airway colonization (other than Aspergillus sp.) regardless of underlying pulmonary co-morbidities
□ Patients with post-transplant mold airway colonization (other than Aspergillus sp.) regardless of underlying pulmonary co-morbidities
□ Patients with pre-transplant non-Candida yeast airway colonization regardless of underlying pulmonary co-morbidities
□ Patients with post-transplant non-Candida yeast airway colonization regardless of underlying pulmonary co-morbidities
□ Patients with pre-transplant Candida sp. airway colonization regardless of underlying pulmonary co-morbidities
□ Patients with post-transplant Candida sp. airway colonization regardless of underlying pulmonary co-morbidities
□ Patients with pre-transplant invasive Aspergillus sp. Infection
□ Patients with pre-transplant invasive mold (other than Aspergillus sp.) infection
□ Patients with pre-transplant non-Candida yeast infection
□ Patients with pre-transplant Candida sp. infection
□ Other
Please describe “Other”
Do patients 3 months but less than 12 months post-lung transplant receive inhaled amphotericin for prophylaxis?
○ All patients receive inhaled amphotericin during this post-transplant period
○ No patients receive inhaled amphotericin during this post-transplant period
○ Some patients receive inhaled amphotericin during this post-transplant period
Which patients receive inhaled amphotericin 3 months but less than 12 months post-lung transplant (Select all that apply)?
□ Patients with a diagnosis of Cystic Fibrosis
□ Patients with bronchiectasis without a diagnosis of Cystic Fibrosis
□ Patients with pre-transplant Aspergillus sp. airway colonization regardless of underlying pulmonary co-morbidities
□ Patients with post-transplant Aspergillus sp. airway colonization regardless of underlying pulmonary co-morbidities
□ Patients with pre-transplant mold airway colonization (other than Aspergillus sp.) regardless of underlying pulmonary co-morbidities
□ Patients with post-transplant mold airway colonization (other than Aspergillus sp.) regardless of underlying pulmonary co-morbidities
□ Patients with pre-transplant non-Candida yeast airway colonization regardless of underlying pulmonary co-morbidities
□ Patients with post-transplant non-Candida yeast airway colonization regardless of underlying pulmonary co-morbidities
□ Patients with pre-transplant Candida sp. airway colonization regardless of underlying pulmonary co-morbidities
□ Patients with post-transplant Candida sp. airway colonization regardless of underlying pulmonary co-morbidities
□ Patients with pre-transplant invasive Aspergillus sp. infection
□ Patients with pre-transplant invasive mold (other than Aspergillus sp.) infection
□ Patients with pre-transplant non-Candida yeast infection
□ Patients with pre-transplant Candida sp. infection
□ Other
Please describe “Other”
Do patients 3 months but less than 12 months post-lung transplant receive systemic triazole(s) for prophylaxis? Triazole therapy includes: fluconazole, voriconazole, itraconazole, posaconazole, isavuconazole.
○ All patients receive systemic triazole therapy during this post-transplant period
○ No patients receive systemic triazole therapy during this post-transplant period
○ Some patients receive triazole(s) during this post-transplant period
Which patients receive systemic triazole(s) 3 months but less than 12 months post-lung transplant (Select all that apply)?
□ Patients with a diagnosis of Cystic Fibrosis
□ Patients with bronchiectasis without a diagnosis of Cystic Fibrosis
□ Patients with pre-transplant Aspergillus spp. airway colonization regardless of underlying pulmonary co-morbidities
□ Patients with post-transplant Aspergillus spp. airway colonization regardless of underlying pulmonary co-morbidities
□ Patients with pre-transplant mold airway colonization (other than Aspergillus spp.) regardless of underlying pulmonary co-morbidities
□ Patients with post-transplant mold airway colonization (other than Aspergillus spp.) regardless of underlying pulmonary co-morbidities
□ Patients with pre-transplant non-Candida yeast airway colonization regardless of underlying pulmonary co-morbidities
□ Patients with pre-transplant Candida sp. airway colonization regardless of underlying pulmonary co-morbidities
□ Patients with post-transplant non-Candida yeast airway colonization regardless of underlying pulmonary co-morbidities
□ Patients with post-transplant Candida sp. airway colonization regardless of underlying pulmonary co-morbidities
□ Patients with pre-transplant invasive Aspergillus spp. infection
□ Patients with pre-transplant invasive mold (other than Aspergillus spp.) infection
□ Patients with pre-transplant non-Candida yeast infection
□ Patients with pre-transplant Candida sp. infection
□ Other
Please describe “Other”
Do patients 3 months but less than 12 months post-lung transplant receive systemic echinocandin(s) for prophylaxis? Echinocandin therapy includes: caspofungin, micafungin, anidulafungin.
○ All patients receive systemic echinocandin during this post-transplant period
○ No patients receive systemic echinocandin therapy during this post-transplant period
○ Some patients receive echinocandin(s) during this post-transplant period
Which patients receive systemic echinocandin(s) 3 months but less than 12 months post-lung transplant (Select all that apply)?
□ Patients with a diagnosis of Cystic Fibrosis
□ Patients with bronchiectasis without a diagnosis of Cystic Fibrosis
□ Patients with pre-transplant Aspergillus sp. airway colonization regardless of underlying pulmonary co-morbidities
□ Patients with post-transplant Aspergillus sp. airway colonization regardless of underlying pulmonary co-morbidities
□ Patients with pre-transplant mold airway colonization (other than Aspergillus sp.) regardless of underlying pulmonary co-morbidities
□ Patients with post-transplant mold airway colonization (other than Aspergillus sp.) regardless of underlying pulmonary co-morbidities
□ Patients with pre-transplant non-Candida yeast airway colonization regardless of underlying pulmonary co-morbidities
□ Patients with post-transplant non-Candida yeast airway colonization regardless of underlying pulmonary co-morbidities
□ Patients with pre-transplant Candida sp. airway colonization regardless of underlying pulmonary co-morbidities
□ Patients with post-transplant Candida sp. airway colonization regardless of underlying pulmonary co-morbidities
□ Patients with pre-transplant invasive Aspergillus sp. infection
□ Patients with pre-transplant invasive mold (other than Aspergillus sp.) infection
□ Patients with pre-transplant non-Candida yeast infection
□ Patients with pre-transplant Candida sp. infection
□ Other
Please describe “Other”
Do patients 3 months but less than 12 months post-lung transplant receive systemic amphotericin for prophylaxis?
○ All patients receive systemic amphotericin during this post-transplant period
○ No patients receive systemic amphotericin during this post-transplant period
○ Some patients receive systemic amphotericin during this post-transplant period
Which patients receive systemic amphotericin 3 months but less than 12 months post-lung transplant (Select all that apply)?
□ Patients with a diagnosis of Cystic Fibrosis
□ Patients with bronchiectasis without a diagnosis of Cystic Fibrosis
□ Patients with pre-transplant Aspergillus sp. airway colonization regardless of underlying pulmonary co-morbidities
□ Patients with post-transplant Aspergillus sp. airway colonization regardless of underlying pulmonary co-morbidities
□ Patients with pre-transplant mold airway colonization (other than Aspergillus sp.) regardless of underlying pulmonary co-morbidities
□ Patients with post-transplant mold airway colonization (other than Aspergillus sp.) regardless of underlying pulmonary co-morbidities
□ Patients with pre-transplant non-Candida yeast airway colonization regardless of underlying pulmonary co-morbidities
□ Patients with post-transplant non-Candida yeast airway colonization regardless of underlying pulmonary co-morbidities
□ Patients with pre-transplant Candida sp. airway colonization regardless of underlying pulmonary co-morbidities
□ Patients with post-transplant Candida sp. airway colonization regardless of underlying pulmonary co-morbidities
□ Patients with pre-transplant invasive Aspergillus sp. infection
□ Patients with pre-transplant invasive mold (other than Aspergillus sp.) infection
□ Patients with pre-transplant non-Candida yeast infection
□ Patients with pre-transplant Candida sp. infection
□ Other
Please describe “Other”
Do patients 12 months or greater post-lung transplant receive inhaled amphotericin for prophylaxis?
○ All patients receive inhaled amphotericin during this post-transplant period
○ No patients receive inhaled amphotericin during this post-transplant period
○ Some patients receive inhaled amphotericin during this post-transplant period
Which patients receive inhaled amphotericin 12 months or greater post-lung transplant (Select all that apply)?
□ Patients with a diagnosis of Cystic Fibrosis
□ Patients with bronchiectasis without a diagnosis of Cystic Fibrosis
□ Patients with pre-transplant Aspergillus sp. airway colonization regardless of underlying pulmonary co-morbidities
□ Patients with post-transplant Aspergillus sp. airway colonization regardless of underlying pulmonary co-morbidities
□ Patients with pre-transplant mold airway colonization (other than Aspergillus sp.) regardless of underlying pulmonary co-morbidities
□ Patients with post-transplant mold airway colonization (other than Aspergillus sp.) regardless of underlying pulmonary co-morbidities
□ Patients with pre-transplant non-Candida yeast airway colonization regardless of underlying pulmonary co-morbidities
□ Patients with post-transplant non-Candida yeast airway colonization regardless of underlying pulmonary co-morbidities
□ Patients with pre-transplant Candida sp. airway colonization regardless of underlying pulmonary co-morbidities
□ Patients with post-transplant Candida sp. airway colonization regardless of underlying pulmonary co-morbidities
□ Patients with pre-transplant invasive Aspergillus sp. infection
□ Patients with pre-transplant invasive mold (other than Aspergillus sp.) infection
□ Patients with pre-transplant non-Candida yeast infection
□ Patients with pre-transplant Candida sp. infection
□ Other
Please describe “Other”
Do patients 12 months or greater post-lung transplant receive systemic triazole(s) for prophylaxis? Triazole therapy includes: fluconazole, voriconazole, itraconazole, posaconazole, isavuconazole.
○ All patients receive systemic triazole therapy during this post-transplant period
○ No patients receive systemic triazole therapy during this post-transplant period
○ Some patients receive triazole(s) during this post-transplant period
Which patients receive systemic triazole 12 months or greater post-lung transplant (Select all that apply)?
□ Patients with a diagnosis of Cystic Fibrosis
□ Patients with bronchiectasis without a diagnosis of Cystic Fibrosis
□ Patients with pre-transplant Aspergillus sp. airway colonization regardless of underlying pulmonary co-morbidities
□ Patients with post-transplant Aspergillus sp. airway colonization regardless of underlying pulmonary co-morbidities
□ Patients with pre-transplant mold airway colonization (other than Aspergillus sp.) regardless of underlying pulmonary co-morbidities
□ Patients with post-transplant mold airway colonization (other than Aspergillus sp.) regardless of underlying pulmonary co-morbidities
□ Patients with pre-transplant non-Candida yeast airway colonization regardless of underlying pulmonary co-morbidities
□ Patients with post-transplant non-Candida yeast airway colonization regardless of underlying pulmonary co-morbidities
□ Patients with pre-transplant Candida sp. airway colonization regardless of underlying pulmonary co-morbidities
□ Patients with post-transplant Candida sp. airway colonization regardless of underlying pulmonary co-morbidities
□ Patients with pre-transplant invasive Aspergillus sp. infection
□ Patients with pre-transplant invasive mold (other than Aspergillus sp.) infection
□ Patients with pre-transplant non-Candida yeast infection
□ Patients with pre-transplant Candida sp. infection
□ Other
Please describe “Other”
Do patients 12 months or greater post-lung transplant receive systemic echinocandin(s) for prophylaxis? Echinocandin therapy includes: caspofungin, micafungin, anidulafungin.
○ All patients receive systemic echinocandin during this period post-lung transplantation
○ No patients receive systemic echinocandin therapy during this post-transplant period
○ Some patients receive echinocandin(s) during this post-transplant period
Which patients receive systemic echinocandins 12 months or greater post-lung transplant (Select all that apply)?
□ Patients with a diagnosis of Cystic Fibrosis
□ Patients with bronchiectasis without a diagnosis of Cystic Fibrosis
□ Patients with pre-transplant Aspergillus sp. airway colonization regardless of underlying pulmonary co-morbidities
□ Patients with post-transplant Aspergillus sp. airway colonization regardless of underlying pulmonary co-morbidities
□ Patients with pre-transplant mold airway colonization (other than Aspergillus sp.) regardless of underlying pulmonary co-morbidities
□ Patients with post-transplant mold airway colonization (other than Aspergillus sp.) regardless of underlying pulmonary co-morbidities
□ Patients with pre-transplant non-Candida yeast airway colonization regardless of underlying pulmonary co-morbidities
□ Patients with post-transplant non-Candida yeast airway colonization regardless of underlying pulmonary co-morbidities
□ Patients with pre-transplant Candida sp. airway colonization regardless of underlying pulmonary co-morbidities
□ Patients with post-transplant Candida sp. airway colonization regardless of underlying pulmonary co-morbidities
□ Patients with pre-transplant invasive Aspergillus sp. infection
□ Patients with pre-transplant invasive mold (other than Aspergillus sp.) infection
□ Patients with pre-transplant non-Candida yeast infection
□ Patients with pre-transplant Candida sp. infection
□ Other
Please describe “Other”
Do patients 12 months or greater post-lung transplant receive systemic amphotericin for prophylaxis?
○ All patients receive systemic amphotericin during this period post-lung transplantation
○ No patients receive systemic amphotericin during this post-transplant period
○ Some patients receive systemic amphotericin during this post-transplant period
Which patients receive systemic amphotericin 12 months or greater post-lung transplant (Select all that apply)?
□ Patients with a diagnosis of Cystic Fibrosis
□ Patients with bronchiectasis without a diagnosis of Cystic Fibrosis
□ Patients with pre-transplant Aspergillus sp. airway colonization regardless of underlying pulmonary co-morbidities
□ Patients with post-transplant Aspergillus sp. airway colonization regardless of underlying pulmonary co-morbidities
□ Patients with pre-transplant mold airway colonization (other than Aspergillus sp.) regardless of underlying pulmonary co-morbidities
□ Patients with post-transplant mold airway colonization (other than Aspergillus sp.) regardless of underlying pulmonary co-morbidities
□ Patients with pre-transplant non-Candida yeast airway colonization regardless of underlying pulmonary co-morbidities
□ Patients with post-transplant non-Candida yeast airway colonization regardless of underlying pulmonary co-morbidities
□ Patients with pre-transplant Candida sp. airway colonization regardless of underlying pulmonary co-morbidities
□ Patients with post-transplant Candida sp. airway colonization regardless of underlying pulmonary co-morbidities
□ Patients with pre-transplant invasive Aspergillus sp. infection
□ Patients with pre-transplant invasive mold (other than Aspergillus sp.) infection
□ Patients with pre-transplant non-Candida yeast infection
□ Patients with pre-transplant Candida sp. infection
□ Other
Please describe “Other”